New-generation triazole antifungal drugs: review of the Phase II and III trials

In this article, the pharmacological, microbiological and clinical development progress from Phase II and III clinical trials with the new generation triazoles albaconazole, isavuconazole, posaconazole, ravuconazole and voriconazole are reviewed. These drugs exhibit a favorable toxicity profile and possess high activity against resistant and emerging fungal pathogens. Pharmacokinetic may be affected by variability in metabolism and/or gastrointestinal absorption. Only voriconazole and posaconazole have been adequately investigated and are now indicated in the treatment and prophylaxis of invasive fungal diseases. Other triazoles; albaconazole, isavuconazole and ravuconazole are under development; therefore, their future use is unknown.

[1]  A. Warris,et al.  Impact of Therapeutic Drug Monitoring of Voriconazole in a Pediatric Population , 2011, The Pediatric infectious disease journal.

[2]  A. Thiébaut,et al.  European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3—2009 Update , 2011, Bone Marrow Transplantation.

[3]  M. Pfaller,et al.  Wild-Type MIC Distributions and Epidemiological Cutoff Values for Posaconazole and Voriconazole and Candida spp. as Determined by 24-Hour CLSI Broth Microdilution , 2010, Journal of Clinical Microbiology.

[4]  J. Dipersio,et al.  Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. , 2010, Blood.

[5]  M. Pfaller,et al.  Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods. , 2010, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[6]  C. Girmenia.  Prophylaxis of invasive fungal diseases in patients with hematologic disorders , 2010, Haematologica.

[7]  H. Einsele,et al.  Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study , 2010, Haematologica.

[8]  F. Grenouillet,et al.  International Retrospective Analysis of 73 Cases of Invasive Fusariosis Treated with Voriconazole , 2010, Antimicrobial Agents and Chemotherapy.

[9]  D. Marriott,et al.  Voriconazole concentrations and outcome of invasive fungal infections. , 2010, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[10]  H. Shimada,et al.  Differences in voriconazole trough plasma concentrations per oral dosages between children younger and older than 3 years of age , 2010, Pediatric blood & cancer.

[11]  J. Turnidge,et al.  Wild-Type MIC Distributions and Epidemiological Cutoff Values for the Triazoles and Six Aspergillus spp. for the CLSI Broth Microdilution Method (M38-A2 Document) , 2010, Journal of Clinical Microbiology.

[12]  D. Niederwieser,et al.  Voriconazole Pharmacokinetics and Safety in Immunocompromised Children Compared to Adult Patients , 2010, Antimicrobial Agents and Chemotherapy.

[13]  M. Srinivasan,et al.  Comparison of natamycin and voriconazole for the treatment of fungal keratitis. , 2010, Archives of ophthalmology.

[14]  C. Lass‐Flörl,et al.  In vitro susceptibility testing in fungi: a global perspective on a variety of methods , 2010, Mycoses.

[15]  W. Melchers,et al.  Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use? , 2009, The Lancet. Infectious diseases.

[16]  W. Haefeli,et al.  Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype. , 2009, British journal of clinical pharmacology.

[17]  G. Krishna,et al.  Effect of Varying Amounts of a Liquid Nutritional Supplement on the Pharmacokinetics of Posaconazole in Healthy Volunteers , 2009, Antimicrobial Agents and Chemotherapy.

[18]  U. Fuhr,et al.  Factors Influencing Pharmacokinetics of Prophylactic Posaconazole in Patients Undergoing Allogeneic Stem Cell Transplantation , 2009, Antimicrobial Agents and Chemotherapy.

[19]  D. Lebeaux,et al.  Therapeutic Drug Monitoring of Posaconazole: a Monocentric Study with 54 Adults , 2009, Antimicrobial Agents and Chemotherapy.

[20]  G. González.  In vitro activities of isavuconazole against opportunistic filamentous and dimorphic fungi. , 2009, Medical mycology.

[21]  J. Sobel,et al.  Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  J. Mehta,et al.  Serial Plasma Voriconazole Concentrations after Allogeneic Hematopoietic Stem Cell Transplantation , 2009, Antimicrobial Agents and Chemotherapy.

[23]  C. Lass‐Flörl,et al.  In Vitro Activity of Isavuconazole against Aspergillus Species and Zygomycetes According to the Methodology of the European Committee on Antimicrobial Susceptibility Testing , 2009, Antimicrobial Agents and Chemotherapy.

[24]  G. Krishna,et al.  Pharmacokinetics and Absorption of Posaconazole Oral Suspension under Various Gastric Conditions in Healthy Volunteers , 2008, Antimicrobial Agents and Chemotherapy.

[25]  J. Guinea,et al.  Isavuconazole: a new and promising antifungal triazole for the treatment of invasive fungal infections. , 2008, Future microbiology.

[26]  D. Denning,et al.  Efficacy of isavuconazole, voriconazole and fluconazole in temporarily neutropenic murine models of disseminated Candida tropicalis and Candida krusei. , 2008, The Journal of antimicrobial chemotherapy.

[27]  D. Andes,et al.  Antifungal Therapeutic Drug Monitoring: Established and Emerging Indications , 2008, Antimicrobial Agents and Chemotherapy.

[28]  A. Schmitt-Hoffmann.  Pharmacokinetics of Isavuconazole in Liver Impairment Preliminary Data , 2008 .

[29]  A. Schmitt-Hoffmann.  No Relevant Food Effect in Man on Isavuconazole Oral Pharmacokinetics Preliminary Data , 2008 .

[30]  Marc H Scheetz,et al.  Posaconazole: An Oral Triazole with an Extended Spectrum of Activity , 2008, The Annals of pharmacotherapy.

[31]  O. Cornely,et al.  Pharmacokinetics of Oral Posaconazole in Neutropenic Patients Receiving Chemotherapy for Acute Myelogenous Leukemia or Myelodysplastic Syndrome , 2008, Pharmacotherapy.

[32]  C. Lass‐Flörl,et al.  Activities of Antifungal Agents against Yeasts and Filamentous Fungi: Assessment according to the Methodology of the European Committee on Antimicrobial Susceptibility Testing , 2008, Antimicrobial Agents and Chemotherapy.

[33]  M. Pfaller,et al.  In Vitro Survey of Triazole Cross-Resistance among More than 700 Clinical Isolates of Aspergillus Species , 2008, Journal of Clinical Microbiology.

[34]  A. Espinel-Ingroff.  Mechanisms of resistance to antifungal agents: yeasts and filamentous fungi. , 2008, Revista iberoamericana de micologia.

[35]  A. Espinel-Ingroff,et al.  Activities of voriconazole, itraconazole and amphotericin B in vitro against 590 moulds from 323 patients in the voriconazole Phase III clinical studies. , 2008, The Journal of antimicrobial chemotherapy.

[36]  Raoul Herbrecht,et al.  Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[37]  T. Peláez,et al.  In Vitro Antifungal Activities of Isavuconazole (BAL4815), Voriconazole, and Fluconazole against 1,007 Isolates of Zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium Species , 2008, Antimicrobial Agents and Chemotherapy.

[38]  J. Meis,et al.  In Vitro Activity of the New Azole Isavuconazole (BAL4815) Compared with Six Other Antifungal Agents against 162 Cryptococcus neoformans Isolates from Cuba , 2008, Antimicrobial Agents and Chemotherapy.

[39]  Thierry Buclin,et al.  Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[40]  M. Pfaller,et al.  Selection of a Surrogate Agent (Fluconazole or Voriconazole) for Initial Susceptibility Testing of Posaconazole against Candida spp.: Results from a Global Antifungal Surveillance Program , 2007, Journal of Clinical Microbiology.

[41]  S. Deresinski,et al.  Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[42]  P. Chandrasekar,et al.  Pharmacokinetics of Oral Posaconazole in Allogeneic Hematopoietic Stem Cell Transplant Recipients with Graft‐versus‐Host Disease , 2007, Pharmacotherapy.

[43]  M. Rinaldi,et al.  In Vitro Susceptibilities of 217 Clinical Isolates of Zygomycetes to Conventional and New Antifungal Agents , 2007, Antimicrobial Agents and Chemotherapy.

[44]  L. Gordon,et al.  Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients , 2007, Cancer.

[45]  W. Melchers,et al.  Multiple-triazole-resistant aspergillosis. , 2007, The New England journal of medicine.

[46]  J. Mehta,et al.  Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy , 2007, Bone Marrow Transplantation.

[47]  H. Seifert,et al.  In Vitro Activities of Isavuconazole and Other Antifungal Agents against Candida Bloodstream Isolates , 2007, Antimicrobial Agents and Chemotherapy.

[48]  D. Ward,et al.  Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[49]  J. Lipton,et al.  Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. , 2007, The New England journal of medicine.

[50]  J. Perfect,et al.  Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. , 2007, The New England journal of medicine.

[51]  D. Denning,et al.  Comparative in vivo activity of BAL4815, the active component of the prodrug BAL8557, in a neutropenic murine model of disseminated Aspergillus flavus. , 2006, The Journal of antimicrobial chemotherapy.

[52]  F. Odds.  Drug evaluation: BAL-8557--a novel broad-spectrum triazole antifungal. , 2006, Current opinion in investigational drugs.

[53]  T. Rogers.  Antifungal drug resistance: limited data, dramatic impact? , 2006, International journal of antimicrobial agents.

[54]  J. Graybill,et al.  Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[55]  Ronald N. Jones,et al.  International Surveillance of Candida spp. and Aspergillus spp.: Report from the SENTRY Antimicrobial Surveillance Program (2003) , 2006, Journal of Clinical Microbiology.

[56]  D. Skiest,et al.  A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[57]  D. Kontoyiannis,et al.  Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[58]  D. Andes,et al.  Voriconazole Therapeutic Drug Monitoring , 2006, Antimicrobial Agents and Chemotherapy.

[59]  M. Schuster,et al.  Posaconazole as Salvage Therapy for Zygomycosis , 2006, Antimicrobial Agents and Chemotherapy.

[60]  A. Schmitt-Hoffmann,et al.  Multiple-Dose Pharmacokinetics and Safety of the New Antifungal Triazole BAL4815 after Intravenous Infusion and Oral Administration of Its Prodrug, BAL8557, in Healthy Volunteers , 2006, Antimicrobial Agents and Chemotherapy.

[61]  C. Beglinger,et al.  Single-Ascending-Dose Pharmacokinetics and Safety of the Novel Broad-Spectrum Antifungal Triazole BAL4815 after Intravenous Infusions (50, 100, and 200 Milligrams) and Oral Administrations (100, 200, and 400 Milligrams) of Its Prodrug, BAL8557, in Healthy Volunteers , 2006, Antimicrobial Agents and Chemotherapy.

[62]  D. Kontoyiannis,et al.  Update on antifungal drug resistance mechanisms of Aspergillus fumigatus. , 2005, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[63]  E. Mellado,et al.  In Vitro Activity of Ravuconazole against 923 Clinical Isolates of Nondermatophyte Filamentous Fungi , 2005, Antimicrobial Agents and Chemotherapy.

[64]  T. Walsh,et al.  Compartmental pharmacokinetics and tissue distribution of the antifungal triazole ravuconazole following intravenous administration of its di-lysine phosphoester prodrug (BMS-379224) in rabbits. , 2005, The Journal of antimicrobial chemotherapy.

[65]  C. Viscoli,et al.  Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial , 2005, The Lancet.

[66]  C. Leonardi,et al.  A phase I/II randomized, double‐blind, placebo‐controlled, dose‐ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis , 2005, Journal of the European Academy of Dermatology and Venereology : JEADV.

[67]  M. Pfaller,et al.  Global Trends in the Antifungal Susceptibility of Cryptococcus neoformans (1990 to 2004) , 2005, Journal of Clinical Microbiology.

[68]  J. Mehta,et al.  Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients , 2005, Bone Marrow Transplantation.

[69]  E. Mellado,et al.  In Vitro Activities of Ravuconazole and Four Other Antifungal Agents against Fluconazole-Resistant or -Susceptible Clinical Yeast Isolates , 2004, Antimicrobial Agents and Chemotherapy.

[70]  M. Pfaller,et al.  Cross-Resistance between Fluconazole and Ravuconazole and the Use of Fluconazole as a Surrogate Marker To Predict Susceptibility and Resistance to Ravuconazole among 12,796 Clinical Isolates of Candida spp , 2004, Journal of Clinical Microbiology.

[71]  J. Peter,et al.  Efficacy, Safety, and Plasma Pharmacokinetics of Escalating Dosages of Intravenously Administered Ravuconazole Lysine Phosphoester for Treatment of Experimental Pulmonary Aspergillosis in Persistently Neutropenic Rabbits , 2004, Antimicrobial Agents and Chemotherapy.

[72]  E. Radwanski,et al.  Pharmacokinetics of Posaconazole Coadministered with Antacid in Fasting or Nonfasting Healthy Men , 2004, Antimicrobial Agents and Chemotherapy.

[73]  F. Marty,et al.  Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. , 2004, The New England journal of medicine.

[74]  J. Perfect,et al.  In Vitro and In Vivo Efficacies of the New Triazole Albaconazole against Cryptococcus neoformans , 2004, Antimicrobial Agents and Chemotherapy.

[75]  M. Pfaller,et al.  In vitro susceptibilities of rare Candida bloodstream isolates to ravuconazole and three comparative antifungal agents. , 2004, Diagnostic microbiology and infectious disease.

[76]  E. Radwanski,et al.  Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. , 2003, British journal of clinical pharmacology.

[77]  M. Pfaller,et al.  Activities of Caspofungin, Itraconazole, Posaconazole, Ravuconazole, Voriconazole, and Amphotericin B against 448 Recent Clinical Isolates of Filamentous Fungi , 2003, Journal of Clinical Microbiology.

[78]  J. Guarro,et al.  Efficacy of Albaconazole (UR-9825) in Treatment of Disseminated Scedosporium prolificans Infection in Rabbits , 2003, Antimicrobial Agents and Chemotherapy.

[79]  J. Perfect,et al.  Voriconazole treatment for less-common, emerging, or refractory fungal infections. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[80]  D. Andes,et al.  In Vivo Pharmacodynamics of a New Triazole, Ravuconazole, in a Murine Candidiasis Model , 2003, Antimicrobial Agents and Chemotherapy.

[81]  B. Potoski,et al.  The safety of voriconazole. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[82]  Richard Sylvester,et al.  Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. , 2002, The New England journal of medicine.

[83]  M. Pfaller,et al.  In Vitro Activities of Ravuconazole and Voriconazole Compared with Those of Four Approved Systemic Antifungal Agents against 6,970 Clinical Isolates of Candida spp , 2002, Antimicrobial Agents and Chemotherapy.

[84]  M. Pfaller,et al.  Antifungal Activities of Posaconazole, Ravuconazole, and Voriconazole Compared to Those of Itraconazole and Amphotericin B against 239 Clinical Isolates of Aspergillus spp. and Other Filamentous Fungi: Report from SENTRY Antimicrobial Surveillance Program, 2000 , 2002, Antimicrobial Agents and Chemotherapy.

[85]  E. Thiel,et al.  Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[86]  T. Patterson,et al.  Efficacy of ravuconazole (BMS-207147) in a guinea pig model of disseminated aspergillosis. , 2002, The Journal of antimicrobial chemotherapy.

[87]  E. Anaissie,et al.  Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. , 2002, The New England journal of medicine.

[88]  J. Meis,et al.  In Vitro Activities of New and Conventional Antifungal Agents against Clinical Scedosporium Isolates , 2002, Antimicrobial Agents and Chemotherapy.

[89]  W. Kreisel,et al.  A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[90]  J. Guarro,et al.  In Vitro Antifungal Activities of the New Triazole UR-9825 against Clinically Important Filamentous Fungi , 2001, Antimicrobial Agents and Chemotherapy.

[91]  M. Pfaller,et al.  International Surveillance of Bloodstream Infections Due toCandida Species: Frequency of Occurrence and In Vitro Susceptibilities to Fluconazole, Ravuconazole, and Voriconazole of Isolates Collected from 1997 through 1999 in the SENTRY Antimicrobial Surveillance Program , 2001, Journal of Clinical Microbiology.

[92]  J. Guarro,et al.  In Vitro Activities of Four Novel Triazoles againstScedosporium spp , 2001, Antimicrobial Agents and Chemotherapy.

[93]  V. Andriole,et al.  Efficacies of Two New Antifungal Agents, the Triazole Ravuconazole and the Echinocandin LY-303366, in an Experimental Model of Invasive Aspergillosis , 2000, Antimicrobial Agents and Chemotherapy.

[94]  M. Pfaller,et al.  In Vitro Activities of Ravuconazole (BMS-207147) against 541 Clinical Isolates of Cryptococcus neoformans , 2000, Antimicrobial Agents and Chemotherapy.

[95]  J. Sobel,et al.  Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[96]  D. Denning,et al.  Practice Guidelines for Diseases Caused by Aspergillus , 2000 .

[97]  T. C. White,et al.  In vitro antifungal activity of BMS-207147 and itraconazole against yeast strains that are non-susceptible to fluconazole. , 1999, Diagnostic microbiology and infectious disease.

[98]  M. Pfaller,et al.  In Vitro Activities of BMS-207147 against Over 600 Contemporary Clinical Bloodstream Isolates of Candida Species from the SENTRY Antimicrobial Surveillance Program in North America and Latin America , 1999, Antimicrobial Agents and Chemotherapy.

[99]  M. Cuenca‐Estrella,et al.  In-vitro comparative activity of UR-9825, itraconazole and fluconazole against clinical isolates of Candida spp. , 1999, The Journal of antimicrobial chemotherapy.

[100]  J Ramis,et al.  New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones. , 1998, Journal of medicinal chemistry.

[101]  K. Katsu,et al.  Efficacy of ER-30346, a novel oral triazole antifungal agent, in experimental models of aspergillosis, candidiasis, and cryptococcosis , 1996, Antimicrobial agents and chemotherapy.

[102]  J. Enders,et al.  Infectious Diseases Society of America. , 1969, Antimicrobial agents and chemotherapy.

[103]  R. Jelliffe,et al.  Voriconazole pharmacokinetics and pharmacodynamics in children. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[104]  B. Thiers.  Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia , 2008 .

[105]  J. Perfect,et al.  Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[106]  D. Denning,et al.  In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp. , 2006, The Journal of antimicrobial chemotherapy.